GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Cash Ratio

Celadon Pharmaceuticals (LSE:CEL) Cash Ratio : 1.15 (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Celadon Pharmaceuticals's Cash Ratio for the quarter that ended in Jun. 2023 was 1.15.

Celadon Pharmaceuticals has a Cash Ratio of 1.15. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Celadon Pharmaceuticals's Cash Ratio or its related term are showing as below:

LSE:CEL' s Cash Ratio Range Over the Past 10 Years
Min: 0.36   Med: 4.23   Max: 25.25
Current: 1.15

During the past 4 years, Celadon Pharmaceuticals's highest Cash Ratio was 25.25. The lowest was 0.36. And the median was 4.23.

LSE:CEL's Cash Ratio is ranked better than
66.6% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs LSE:CEL: 1.15

Celadon Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Celadon Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Cash Ratio Chart

Celadon Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Ratio
0.01 0.36 - 4.23

Celadon Pharmaceuticals Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Ratio Get a 7-Day Free Trial - 25.25 6.45 4.23 1.15

Competitive Comparison of Celadon Pharmaceuticals's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Celadon Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celadon Pharmaceuticals's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celadon Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Celadon Pharmaceuticals's Cash Ratio falls into.



Celadon Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Celadon Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.819/1.376
=4.23

Celadon Pharmaceuticals's Cash Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash Ratio (Q: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.877/1.626
=1.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celadon Pharmaceuticals  (LSE:CEL) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Celadon Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Celadon Pharmaceuticals (LSE:CEL) Business Description

Traded in Other Exchanges
N/A
Address
32-33 Cowcross Street, London, GBR, EC1M 6DF
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines